Modality
Vaccine
MOA
MDM2i
Target
CDK2
Pathway
Sphingolipid
ETAsthma
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Sep 2027
Phase 1Current
NCT08802397
1,844 pts·ET
2018-02→2027-09·Not yet recruiting
NCT05722474
956 pts·ET
2017-06→TBD·Completed
2,800 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-081.4y awayInterim· ET
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Complet…
P1
Not yet…
Catalysts
Interim
2027-09-08 · 1.4y away
ET
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08802397 | Phase 1 | ET | Not yet recr... | 1844 | HAM-D |
| NCT05722474 | Phase 1 | ET | Completed | 956 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 |